|   In the News

Atlas launches second Cambridge biotech to tackle vision loss

In September, the Swiss drug giant Novartis paid $150 million for a Cambridge startup that had developed a pair of potential gene therapies to restore vision to people with blindness stemming from genetic diseases. It was a sizable return for the biotech, which had used roughly half of the $21 million in venture capital it had raised after its founding about 17 months earlier by Atlas Venture.

Read more.

  |   Press Release

Atlas Venture Welcomes Samantha Truex as Venture Partner

Atlas Venture, a leading early stage venture capital firm, announced today that Samantha (Sam) Truex is joining the firm as a venture partner. Sam will work with the Atlas team to start and build new biotech companies aimed at bringing therapeutic innovations to patients.

Read more.

  |   From the Trenches

You Want To Be A CBO? Four Tips To Set You On Your Way

Most of the titles in a biotech C-suite are generally self-explanatory. The Chief Technical and Manufacturing Officer runs operations in CMC and analytics. The Chief Financial Officer handles financial strategy and investor relations. The Chief Commercial Officer prepares for bringing investigational therapies to market.

By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC

Read more.

  |   From the Trenches

The Unsung Heroes Of Entrepreneurial Companies

The role of the core in making an organization great and how we do right by them.

Small organizations are amazing for the impact they can have relative to their size.

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.

  |   LifeSciVC

Five Macro Risks To Biotech Coming Out of Washington

By Bruce Booth, DPhil, Partner

Despite saving the world from COVID, pharma and biotech are still in the crosshairs of many politicians. With many anti-Pharma politicians and regulators emboldened in the current environment, and with more aggressive tax and spending policy in the works, there a number of risks to biotech over the next 1-2 years out of Washington.

Read more.